Munich

• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc … Recruiting
  2022-500676-59-00 4 2025-12-18 EBV-positive nasopharyngeal carcinoma
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 11 2025-12-18 Neovascular age-related macular degeneration
• A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting
  2024-513008-32-00 4 2025-12-17 Adenocarcinoma of the gastroesophageal junction
• ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha … Recruiting
  2025-522718-22-00 4 2025-12-16 Gastroesophageal Adenocarcinoma
• A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch … Recruiting
  2025-523009-14-00 4 2025-12-16 Bronchiectasis with chronic pseudomonas aeruginosa colonization
• QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers Recruiting
  2025-521735-36-00 7 2025-12-15 Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) or chronic
• NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophag … Recruiting
  2024-519993-38-00 3 2025-12-12 resectable esophagogastric adenocarcinoma
• Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting
  2025-520831-18-00 4 2025-12-12 Primary Sjogren’s Disease
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS) Recruiting
  2024-515982-32-00 6 2025-12-09 Overweight or Obesity
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• FUTURE Recruiting
  2024-517573-24-00 4 2025-12-08 Colorectal cancer
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 9 2025-12-05 Advanced solid tumors
• Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH) Recruiting
  2024-517009-99-00 4 2025-12-03 Pulmonary arterial hypertension
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting
  2025-521644-37-00 4 2025-11-28 locally advanced or metastatic penile squamous cell carcinoma
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis

Showing 217–240 of 1,080 trials